Grundläggande statistik
| CIK | 1734768 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to IMV Inc
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| September 22, 2023 |
As filed with the Securities and Exchange Commission on September 22, 2023 As filed with the Securities and Exchange Commission on September 22, 2023 Registration Nos. |
|
| September 22, 2023 |
As filed with the Securities and Exchange Commission on September 22, 2023 As filed with the Securities and Exchange Commission on September 22, 2023 Registration Nos. |
|
| September 22, 2023 |
As filed with the Securities and Exchange Commission on September 22, 2023 As filed with the Securities and Exchange Commission on September 22, 2023 Registration Nos. |
|
| September 22, 2023 |
As filed with the Securities and Exchange Commission on September 22, 2023 As filed with the Securities and Exchange Commission on September 22, 2023 Registration No. |
|
| September 22, 2023 |
As filed with the Securities and Exchange Commission on September 22, 2023 As filed with the Securities and Exchange Commission on September 22, 2023 Registration Nos. |
|
| September 22, 2023 |
As filed with the Securities and Exchange Commission on September 22, 2023 As filed with the Securities and Exchange Commission on September 22, 2023 Registration Nos. |
|
| September 22, 2023 |
As filed with the Securities and Exchange Commission on September 22, 2023 As filed with the Securities and Exchange Commission on September 22, 2023 Registration No. |
|
| September 22, 2023 |
As filed with the Securities and Exchange Commission on September 22, 2023 As filed with the Securities and Exchange Commission on September 22, 2023 Registration No. |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38480 IMV INC. (Exact name of registrant as specified in its charter) 13 |
|
| July 26, 2023 |
Filed by e3 Filing, Computershare 1-800-973-3274 - IMV Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2023 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, N |
|
| July 26, 2023 |
IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process Exhibit 99.1 Exhibit 99.1 Media Release IMV Inc. Announces Update on CCAA Proceedings and Sales and Investment Solicitation Process DARTMOUTH, Nova Scotia — (BUSINESS WIRE) — July 26, 2023, IMV Inc. (the “Company” or “IMV”), recently announced an update on the Sales and Investment Solicitation Process (the “SISP”) implemented as part of its ongoing proceedings under the Companies' Creditors Arrang |
|
| May 8, 2023 |
IMV Receives NASDAQ Delisting Notice Exhibit 99.1 Media Release IMV Receives NASDAQ Delisting Notice DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.—(BUSINESS WIRE)—May 8, 2023, IMV Inc. (the “Company” or “IMV”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that it was notified |
|
| May 8, 2023 |
Filed by e3 Filing, Computershare 1-800-973-3274 - IMV Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2023 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, No |
|
| March 31, 2023 |
Filed by e3 Filing, Computershare 1-800-973-3274 - IMV Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, |
|
| March 31, 2023 |
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Exhibit 99.1 Exhibit 99.1 Media Release IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. – March 31, 2023 - IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platform to treat solid and hematologic cancers, today announced |
|
| March 28, 2023 |
Filed by e3 Filing, Computershare 1-800-973-3274 - IMV Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, |
|
| March 28, 2023 |
IMV Inc. Announces Changes to Its Board of Directors Exhibit 99.1 Exhibit 99.1 Media Release IMV Inc. Announces Changes to Its Board of Directors Dartmouth, Nova Scotia, and Cambridge, Mass., March 27, 2023 , IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform, to treat solid and hematologic cancers, today announced changes to its board of directors as Sherma |
|
| March 16, 2023 |
Filed by e3 Filing, Computershare 1-800-973-3274 - IMV Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, |
|
| March 16, 2023 |
Employment Contract, effective June 14, 2021, by and between IMV Inc. and Jeremy R. Graff EX-4.9 10 exhibit4-9.htm EMPLOYMENT CONTRACT, EFFECTIVE JUNE 14, 2021 Exhibit 4.9 THIS EMPLOYMENT CONTRACT made effective as of the June 14, 2021 BETWEEN IMV INC., a corporation incorporated pursuant to the laws of the Province of Nova Scotia and having its registered office at 130 Eileen Stubbs Ave, Dartmouth, NS B3B 2C4 (the “Corporation”) OF THE FIRST PART - and OF THE SECOND PART Jeremy R. Gra |
|
| March 16, 2023 |
License Agreement dated July 12, 2010 by and between MERCK KGaA and Immunovaccine Technologies Inc. Exhibit 4.2 Exhibit 4.2 CERTAIN INFORMATION (INDICATED BY [***] or [REDACTED]) HAS BEEN EXCLUDED FROM THE VERSION OF THIS DOCUMENT FILED AS AN EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. VERSION FOR SEDAR FILING LICENSE AGREEMENT BETWEEN MERCK KGaA [***] [***] AND IMMUNOVACCINE TECHNOLOGIES, INC. DATED 12 JULY 2010 LICE |
|
| March 16, 2023 |
Management’s Discussion and Analysis for the year ended December 31, 2022 EX-15.2 19 exhibit15-2.htm MANAGEMENTS DISCUSSION AND ANALYSIS FOR THE YEAR ENDED DECEMBER 31, 2022 Exhibit 15.2 Management’s Report on Financial Position and Operating Results For the year ended December 31, 2022 MANAGEMENT DISCUSSION AND ANALYSIS (“MD&A”) The following analysis provides a review of the audited annual consolidated results of operations, financial condition, and cash flows for the |
|
| March 16, 2023 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Financial Officer Exhibit 12.2 Exhibit 12.2 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Brittany Davison, certify that: 1. I have reviewed this annual report on Form 20-F of IMV Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under |
|
| March 16, 2023 |
Exhibit 11.1 Code of Business Conduct Adopted: 30MAY2018Last reviewed: November 10, 2022 CODE OF BUSINESS CONDUCT PURPOSE AND SCOPE The Board of Directors of IMV Inc. (the “Corporation”) has adopted this Code of Business Conduct (the “Code”) in order to: (a) promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest; (b) promote full, fair, accur |
|
| March 16, 2023 |
Rule 13a-14(a)/15d-14(a) Certification of Chief Executive Officer Exhibit 12.1 Exhibit 12.1 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Andrew Hall, certify that: 1. I have reviewed this annual report on Form 20-F of IMV Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which |
|
| March 16, 2023 |
Funding Certificate dated June 21, 2022 Exhibit 4.1.1 Exhibit 4.1.1 FUNDING CERTIFICATE The undersigned, being the duly elected Snr. VP of Finance and Corporate Secretary of IMV INC., a corporation existing under the laws of Canada (“IMV”), IMMUNOVACCINE TECHNOLOGIES INC., a corporation existing under the laws of the Province of Nova Scotia (“Immunovaccine”) and IMV USA INC., a Delaware corporation (“IMV USA”) and together with IMV and |
|
| March 16, 2023 |
Employment Contract, effective September 15, 2022, by and between IMV Inc. and Brittany Davison EX-4.8 9 exhibit4-8.htm EMPLOYMENT CONTRACT, EFFECTIVE SEPTEMBER 15, 2022 Exhibit 4.8 THIS EMPLOYMENT CONTRACT made effective as of September 15, 2022 BETWEEN: IMV INC., a corporation incorporated pursuant to the laws of the Province of Nova Scotia and having its registered office at 130 Eileen Stubbs Ave, Dartmouth, NS B3B 2C4 (the “Corporation”) - and Brittany Davison (the “Executive”) Dartmouth |
|
| March 16, 2023 |
Exhibit 13.2 Exhibit 13.2 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, as the Chief Accounting Officer acting as Chief Financial Officer of IMV Inc. certifies that, to the best of her knowledge and belief, the annual report on Form 20-F for the fiscal year ended December 31, 2022, which accompanies this certification, fully complies with the requirements |
|
| March 16, 2023 |
Exhibit 13.1 Exhibit 13.1 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, as the Chief Executive Officer of IMV Inc. certifies that, to the best of his knowledge and belief, the annual report on Form 20-F for the fiscal year ended December 31, 2022, which accompanies this certification, fully complies with the requirements of Section 13(a) or 15(d), as appl |
|
| March 16, 2023 |
EX-15.1 18 exhibit15-1.htm CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statements on Form F-10 (No. 333-266082), as amended, and Form S-8 (Nos. 333-225363, 333-238706, 333-239550, 333-263867 and 333-268936) of IMV Inc. of our report dated March |
|
| March 16, 2023 |
Exhibit 4.6 Exhibit 4.6 LEASE BETWEEN TNC 120-140 EILEEN STUBBS LTD. AND IMMUNOVACCINE TECHNOLOGIES INC. TABLE OF CONTENTS Article 1.00 – INTERPRETATION 2 1.1 Defined Terms 2 1.2 Schedules 10 1.3 Agreement to Act Reasonably 11 1.4 Approval in Writing 11 1.5 Delegation of Authority 11 1.6 Interpretation 11 Article 2.00 - PREMISES 12 2.1 Premises 12 2.2 Use of Common Areas 12 2.3 Examination and Acc |
|
| March 16, 2023 |
Exhibit 99.1 Exhibit 99.1 Media Release IMV Inc. Announces Strategic Update as well as Fourth Quarter and Full Year 2022 Financial and Operational Results Advanced lead candidate, MVP-S, in two global Phase 2B clinical trials and enhanced the scientific differentiation of the DPX platform Observed multiple complete clinical responses in relapsed/refractory DLBCL and expect to complete enrollment o |
|
| March 16, 2023 |
Exhibit 4.3 Exhibit 4.3 CERTAIN INFORMATION (INDICATED BY [***]) HAS BEEN EXCLUDED FROM THE VERSION OF THIS DOCUMENT FILED AS AN EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December 16, 2022, between IMV Inc., a corporatio |
|
| March 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| March 16, 2023 |
Form of Deferred Share Unit Agreement EX-4.10-1 11 exhibit4-10-1.htm FORM OF DEFERRED SHARE UNIT AGREEMENT Exhibit 4.10.1 DEFERRED Share Unit grant letter This deferred share unit grant letter is entered into between IMV Inc. (the “Corporation”) and the Participant named below pursuant to the Corporation’s deferred share unit plan (the “Plan”), a copy of which is incorporated by reference herein, and confirms the following Deferred Sh |
|
| March 16, 2023 |
Employment Contract, effective January 1, 2022, by and between IMV USA Inc. and Andrew Hall Exhibit 4.7 Exhibit 4.7 CERTAIN INFORMATION (INDICATED BY [***]) HAS BEEN EXCLUDED FROM THE VERSION OF THIS DOCUMENT FILED AS AN EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIS EMPLOYMENT CONTRACT is entered into effective as of January 1st, 2022 (the “Effective Date”) BETWEEN: IMV USA INC., a corporation incorporated |
|
| March 16, 2023 |
Articles of Incorporation and By-laws of IMV Inc. EX-1.1 2 exhibit1-1.htm ARTICLES OF INCORPORATION AND BY-LAWS OF IMV INC. Exhibit 1.1 Certificate of Amendment Certificat de modification Canada Business Corporations Act Loi canadienne sur les sociétés par actions IMV INC. Corporate name / Dénomination sociale 677457-1 Corporation number / Numéro de société I HEREBY CERTIFY that the articles of the above-named corporation are amended under sectio |
|
| March 16, 2023 |
Lease dated July 26, 2021 by and between GiGi Capital, LLC and IMV USA Inc. EX-4.5 6 exhibit4-5.htm LEASE DATED JULY 26, 2021 Exhibit 4.5 LEASE This lease (the “Lease”) is dated as of July 26th, 2021, between GiGi Capital, LLC having a place of business at 10 Rogers Street #121, Cambridge, MA 02142 (the “Lessor”) and IMV USA INC. a Delaware Corporation., presently having its normal place of business at 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, Nova Scotia, B3B 2C4, C |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2023 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registra |
|
| March 9, 2023 |
Exhibit 99.1 Exhibit 99.1 Media Release IMV Inc. to Announce Fourth Quarter and Fiscal Year 2022 Results and Host a Conference Call and Webcast on March 16, 2023 Dartmouth, Nova Scotia, and Cambridge, Mass., March 9, 2023 , IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic |
|
| February 14, 2023 |
CA:IMV / IMV Inc / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-imv123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* IMV Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 44974L301 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan |
|
| February 13, 2023 |
Exhibit 99.1 IMV Inc. Presents Positive Initial Results From The MVP-S Phase 2B VITALIZE Trial Early analysis reveals clinically meaningful activity in refractory DLBCL patients Multiple confirmed complete responses observed in heavily pre-treated patients No adverse safety and tolerability signal reported, consistent with previous clinical trials DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass., Feb 13 |
|
| February 13, 2023 |
Filed by e3 Filing, Computershare 1-800-973-3274 - IMV Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2023 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmout |
|
| February 3, 2023 |
IMV / IMV Inc. / FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC - AMENDMENT NO. 2 Passive Investment SC 13G/A 1 eh23032709913ga2-imv.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* IMV INC. (Name of Issuer) Common Shares (Title of Class of Securities) 44974L103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desig |
|
| January 9, 2023 |
6-K 1 imv6knr.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2023 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2023 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 1 |
|
| January 9, 2023 |
Exhibit 99.1 IMV Inc. Announces Update and Planned 2023 Milestones to Advance Clinical Development of its Lead Therapeutic, MVP-S Presenting details on initial response data from the ongoing VITALIZE DLBCL trial at the Immuno-Oncology 360° conference on February 10, 2023 Expects preliminary clinical response data from the AVALON Phase 2b trial in H2 2023 Recently strengthened financial position wi |
|
| December 22, 2022 |
Certificate of Amendment Canada Business Corporations Act Exhibit 99.2 Certificate of Amendment Canada Business Corporations Act Certificat de modification Loi canadienne sur les soci?t?s par actions IMV INC. Corporate name / D?nomination sociale 677457-1 Corporation number / Num?ro de soci?t? I HEREBY CERTIFY that the articles of the above-named corporation are amended under section 178 of the Canada Business Corporations Act as set out in the attached |
|
| December 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| December 22, 2022 |
Exhibit 99.1 IMV INC. and COMPUTERSHARE TRUST COMPANY OF CANADA FIRST SUPPLEMENTAL WARRANT INDENTURE December 8, 2022 THIS FIRST SUPPLEMENTAL WARRANT INDENTURE dated as of December 8, 2022. BETWEEN: IMV INC., a corporation governed by the laws of Canada; (hereinafter called the ?Corporation?); AND: COMPUTERSHARE TRUST COMPANY OF CANADA, a trust company existing under the laws of Canada and authori |
|
| December 21, 2022 |
As filed with the Securities and Exchange Commission on December 21, 2022 As filed with the Securities and Exchange Commission on December 21, 2022 Registration No. |
|
| December 21, 2022 |
Exhibit 4.1 IMV INC. AMENDED DEFERRED SHARE UNIT PLAN Article 1 INTRODUCTION 1.1 Purpose The purpose of the Plan is to provide Participants with an opportunity to receive a portion or all of their compensation in Deferred Share Units. The Plan aims to align the interests of Participants with those of the shareholders of the Corporation. The Plan is meant to qualify under paragraph 6801(d) of the I |
|
| December 21, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) IMV Inc. (Exact Name of Registrant as Specified in its Charter) Table 1-Newly Registered Securities Security Type Security Class Title Fee Calculation Rule or Instruction Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Fees to Be Paid Equity Com |
|
| December 20, 2022 |
6-K 1 tm2233103d16k.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicat |
|
| December 20, 2022 |
PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED JULY 22, 2022 SUPPL 1 tm2232776-2suppl.htm SUPPL TABLE OF CONTENTS Filed pursuant to General Instruction II.L of Form F-10 File No. 333-266082 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement (the “Prospectus Supplement”), together with the accompanying short form base shelf prospectus dated July 22, 2022 to |
|
| December 20, 2022 |
Exhibit 99.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?) is dated as of , between IMV Inc., a corporation incorporated under the Canada Business Corporations Act (the ?Company?), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a ?Purchaser? and collectively the ?Purchasers?). WHEREAS, subject to the te |
|
| December 20, 2022 |
PREFUNDED COMMON SHARE PURCHASE WARRANT imv iNC. Exhibit 99.4 EXHIBIT A-2 PREFUNDED COMMON SHARE PURCHASE WARRANT imv iNC. Warrant Shares: Initial Exercise Date: December , 2022 THIS PREFUNDED COMMON SHARE PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the dat |
|
| December 20, 2022 |
Exhibit 99.1 McCarthy Tétrault S.E.N.C.R.L., s.r.l. 500, Grande Allée Est, 9e étage Québec, QC G1R 2J7 Canada December 19, 2022 IMV Inc. 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, NS B3B 2C4 Dear Sirs/Mesdames: Re: IMV Inc. - Registration Statement on Form F-10 (File No. 333-266082) We refer to the prospectus supplements, each dated December 19, 2022, to the base shelf prospectus incorporated i |
|
| December 20, 2022 |
FORM 51-102F3 MATERIAL CHANGE REPORT OF IMV INC. Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT OF IMV INC. 1. Name and Address of Corporation IMV Inc. (?IMV? or the ?Corporation?) 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, Nova Scotia B3B 2C4 2. Date of Material Change December 20, 2022 3. News Release On December 16 and December 20, 2022, IMV issued a news release through the services of Business Wire with respect to the material change |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| December 20, 2022 |
Exhibit 99.1 Media Release IMV Announces Closing of US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., December 20, 2022-(BUSINESS WIRE)-IMV Inc. (?IMV? or the ?Company?) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based the Company?s immune-educating platform DPX?, to |
|
| December 20, 2022 |
COMMON SHARE PURCHASE WARRANT imv iNC. Exhibit 99.3 EXHIBIT A-1 COMMON SHARE PURCHASE WARRANT imv iNC. Warrant Shares: Initial Exercise Date: December , 2022 THIS COMMON SHARE PURCHASE WARRANT (the ?Warrant?) certifies that, for value received, or its assigns (the ?Holder?) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the ?Initi |
|
| December 19, 2022 |
PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED JULY 22, 2022 TABLE OF CONTENTS ?Filed pursuant to General Instruction II.L of Form F-10? ?File No. 333-266082? No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement (the ?Prospectus Supplement?), together with the accompanying short form base shelf prospectus dated July 22, 2022 to which it relates, as amended or s |
|
| December 16, 2022 |
Filed by e3 Filing, Computershare 1-800-973-3274 - IMV Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmout |
|
| December 16, 2022 |
IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules Exhibit 99.1 Exhibit 99.1 Media Release IMV Announces US$9 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., December 16, 2022-(BUSINESS WIRE)-IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company advancing a portfolio of therapies based the Company’s immune-educating platform DPX®, |
|
| December 15, 2022 |
6-K 1 imv6knr.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF DECEMBER, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite |
|
| December 15, 2022 |
Exhibit 99.1 Exhibit 99.1 IMV Inc. Announces Initial Data from the Ongoing Phase 2B VITALIZE Trial in Patients with r/r DLBCL Complete responses were observed in patients who received at least three previous lines of treatment (including CAR-T's) Recent clinical data add to the growing enthusiasm for the therapeutic potential of cancer vaccines in combination with checkpoint inhibitors Oral presen |
|
| December 13, 2022 |
IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split Exhibit 99.1 Exhibit 99.1 Media Release IMV Commences Trading on the TSX and Nasdaq Post-Reverse Stock Split DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., December 13, 2022 - IMV Inc. (the “Corporation” or “IMV”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cance |
|
| December 13, 2022 |
6-K 1 imv6knr.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF DECEMBER, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite |
|
| December 7, 2022 |
Filed by e3 Filing, Computershare 1-800-973-3274 - IMV Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmout |
|
| December 7, 2022 |
IMV Shareholders Approve Reverse Stock Split at 88% Exhibit 99.1 Exhibit 99.1 Media Release IMV Shareholders Approve Reverse Stock Split at 88% IMV’s common shares expected to begin trading on a split-adjusted basis on December 13, 2022 DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., December 7, 2022 - IMV Inc. (the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies bas |
|
| November 25, 2022 |
IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED NOVEMBER 25, 2022 Exhibit 99.1 Media Release IMV Receives Nasdaq Notification Regarding Market Value of Listed Securities DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. - November 25, 2022 - IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platfor |
|
| November 25, 2022 |
6-K 1 imv6knr.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF NOVEMBER, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite |
|
| November 16, 2022 |
IMV Inc. Announces Third Quarter 2022 Financial and Operational Results EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED NOVEMBER 10, 2022 Exhibit 99.1 Media Release IMV Inc. Announces Third Quarter 2022 Financial and Operational Results DARTMOUTH, Nova Scotia, November 10, 2022, IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or the “Company”), a clinical-stage biopharmaceutical company developing a portfolio of immune-educating therapies based on its novel DPX® platform to trea |
|
| November 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| November 10, 2022 |
6-K 1 imv6kq3fs.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF NOVEMBER, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Sui |
|
| November 10, 2022 |
Exhibit 99.2 Management?s Report on Financial Position and Operating Results For the three and nine months ended September 30, 2022 MANAGEMENT DISCUSSION AND ANALYSIS (?MD&A?) The following analysis provides a review of the unaudited interim condensed consolidated results of operations, financial condition, and cash flows for the three and nine months ended September 30, 2022 (?Q3 2022?), with inf |
|
| November 10, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.3 4 exhibit99-3.htm CEO CERTIFICATION Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Andrew Hall, Chief Executive Officer of IMV Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of IMV Inc. (the “issuer”) for the interim period ended September 30, 2022. 2. No misrepresentat |
|
| November 10, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Brittany Davison, Chief Accounting Officer acting as Chief Financial Officer of IMV Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of IMV Inc. (the ?issuer?) for the interim period ended September 30, 2022. 2. No misrepresentations |
|
| November 10, 2022 |
Unaudited Interim Condensed Consolidated Financial Statements September 30, 2022 Exhibit 99.1 Unaudited Interim Condensed Consolidated Financial Statements September 30, 2022 November 10, 2022 Management?s Responsibility for Financial Reporting The accompanying unaudited interim condensed consolidated financial statements of IMV Inc. (the ?Corporation?) are the responsibility of management and have been approved by the Board of Directors. The unaudited interim condensed consol |
|
| October 28, 2022 |
NOTICE OF SPECIAL MEETING OF SHAREHOLDERS Exhibit 99.1 NOTICE OF SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the special meeting of the shareholders (the ?Meeting?) of IMV Inc. (the ?Corporation?) will be held in virtual form only at 11:00 a.m. ET, on December 7, 2022, for the purposes of: 1. consider and, if deemed advisable, approve a special resolution, the text of which is set out in Schedule ?A? to the management info |
|
| October 28, 2022 |
Exhibit 99.4 VIA SEDAR October 28, 2022 To: British Columbia Securities Commission Alberta Securities Commission Financial and Consumer Affairs Authority of Saskatchewan The Manitoba Securities Commission Ontario Securities Commission Autorit? des march?s financiers Nova Scotia Securities Commission Office of the Superintendent of Securities, Service Newfoundland and Labrador RE: Abridgement of ti |
|
| October 28, 2022 |
Exhibit 99.3 |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regist |
|
| October 28, 2022 |
Exhibit 99.2 DRAFT October 21, 2022 IMV INC. NOTICE OF SPECIAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATION CIRCULAR OF IMV INC. October 28, 2022 130 Eileen Stubbs Avenue Tel (902) 492-1819 Suite 19 Fax (902) 492-0888 Dartmouth, Nova Scotia Web: http://www.imv-inc.com/ B3B 2C4 These materials are important and require your immediate attention. If you have questions or require assistance with |
|
| October 12, 2022 |
Filed by e3 Filing, Computershare 1-800-973-3274 - IMV Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth |
|
| October 12, 2022 |
Exhibit 99.1 October 12, 2022 1500 Robert-Bourassa Blvd., 7th Floor Montreal QC, H3A 3S8 www.computershare.com To: All Canadian Securities Regulatory Authorities NASDAQ Exchange Subject: IMV INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Special Meeting Record Date for Notice of Meeting : October 24, 2 |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regi |
|
| September 16, 2022 |
FORM 51-102F3 MATERIAL CHANGE REPORT Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT Item 1: Name and Address of Company IMV Inc. (?IMV? or the ?Corporation?) 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, Nova Scotia B3B 2C4 Item 2: Date of Material Change September 15, 2022. Item 3: News Release On September 15, 2022, IMV issued a news release through the services of Business Wire with respect to the material change described bel |
|
| September 15, 2022 |
Exhibit 99.1 Media Release IMV Inc. Announces Strategic Reorganization Reorganization enhances organizational focus on strategic priorities Clinical update on DLBCL patients in Phase 2B VITALIZE trial to be provided in September Appointment of Dr. Saman Maleki to Board of Directors Brittany Davison promoted to Chief Accounting Officer DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass., September 15, 2022, |
|
| September 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regi |
|
| September 1, 2022 |
IMV Inc. to Present at Two Investor Conferences in September Exhibit 99.1 Media Release IMV Inc. to Present at Two Investor Conferences in September DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. ? September 01, 2022 - IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX? platform to treat solid and hematologic cancers, today announced that members of IMV?s executive management te |
|
| September 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regi |
|
| August 12, 2022 |
Exhibit 99.1 Media Release IMV Inc. Announces Second Quarter 2022 Financial and Operational Results Patient recruitment in the Phase 2B VITALIZE DLBCL trial of MVP-S plus Keytruda continues to track well, with first results expected in Q3 2022. Matthew J. Matasar, MD from Memorial Sloan Kettering Cancer Center, has joined VITALIZE as lead principal investigator of the study. First patient dosed in |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registr |
|
| August 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registr |
|
| August 11, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Brittany Davison, Snr. VP Finance acting as Chief Financial Officer of IMV Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of IMV Inc. (the ?issuer?) for the interim period ended June 30, 2022. 2. No misrepresentations: Based on my |
|
| August 11, 2022 |
EX-99.2 3 exhibit99-2.htm MANAGEMENT DISCUSSION AND ANALYSIS FOR THE PERIOD ENDED JUNE 30, 2022 Exhibit 99.2 Management’s Report on Financial Position and Operating Results For the three and six months ended June 30, 2022 MANAGEMENT DISCUSSION AND ANALYSIS (“MD&A”) The following analysis provides a review of the unaudited interim condensed consolidated results of operations, financial condition, a |
|
| August 11, 2022 |
Unaudited Interim Condensed Consolidated Financial Statements June 30, 2022 EX-99.1 2 exhibit99-1.htm INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED JUNE 30, 2022 Exhibit 99.1 Unaudited Interim Condensed Consolidated Financial Statements June 30, 2022 August 10, 2022 Management’s Responsibility for Financial Reporting The accompanying unaudited interim condensed consolidated financial statements of IMV Inc. (the “Corporation”) are the responsibility of management and h |
|
| August 11, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.3 4 exhibit99-3.htm CEO CERTIFICATION Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Andrew Hall, Chief Executive Officer of IMV Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of IMV Inc. (the “issuer”) for the interim period ended June 30, 2022. 2. No misrepresentations: |
|
| August 5, 2022 |
PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED JULY 22, 2022 TABLE OF CONTENTS Filed pursuant to General Instruction II.L of Form F-10 File No. 333-266082 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement (the “Prospectus Supplement”), together with the accompanying short form base shelf prospectus dated July 22, 2022 to which it relates, as amended or sup |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada (Address of principal executive offices) I |
|
| August 5, 2022 |
Consent of McCarthy Tétrault LLP Exhibit 99.3 August 4, 2022 Consent of McCarthy T?trault LLP We hereby consent to the use of our name under the headings ?Documents Filed as Part of the U.S. Registration Statement? and ?Legal Matters?, and to the reference to our name and use of our opinion under the heading ?Certain Canadian Federal Income Tax Considerations? in the prospectus supplement dated August 4, 2022 relating to the offe |
|
| August 5, 2022 |
IMV INC. EQUITY DISTRIBUTION AGREEMENT Exhibit 99.2 IMV INC. EQUITY DISTRIBUTION AGREEMENT August 4, 2022 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: As further set forth in this agreement (this ?Agreement?), IMV Inc., a company organized under the laws of Canada (the ?Company?), proposes to issue and sell from time to time through Piper Sandler & Co. (the ?Agent?), as sa |
|
| August 5, 2022 |
6-K 1 imv6knr.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF AUGUST, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 |
|
| August 5, 2022 |
IMV Re-Establishes its At-the-Market Facility under Renewed Base Shelf Prospectus Exhibit 99.1 Media Release IMV Re-Establishes its At-the-Market Facility under Renewed Base Shelf Prospectus DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. ? August 5, 2022 - IMV Inc. (?IMV? or the ?Company?) (Nasdaq: IMV; TSX: IMV) a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX? platform to treat solid and hematologic cancers, today announced that |
|
| August 5, 2022 |
Exhibit 99.1 Media Release IMV Inc. to Announce Second Quarter 2022 Results and Host a Conference Call and Webcast on August 11, 2022 DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. ? August 4, 2022 - IMV Inc. (Nasdaq: IMV; TSX: IMV) (?IMV? or the ?Company?) a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cance |
|
| August 5, 2022 |
IMV Re-Establishes its At-the-Market Facility under Renewed Base Shelf Prospectus Exhibit 99.1 Media Release IMV Re-Establishes its At-the-Market Facility under Renewed Base Shelf Prospectus DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. ? August 5, 2022 - IMV Inc. (?IMV? or the ?Company?) (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX? platform to treat solid and hematologic cancers, today announced tha |
|
| August 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registr |
|
| August 4, 2022 |
PROSPECTUS SUPPLEMENT TO THE SHORT FORM BASE SHELF PROSPECTUS DATED JULY 22, 2022 TABLE OF CONTENTS Filed pursuant to General Instruction II.L of Form F-10 File No. 333-266082 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement, together with the short form base shelf prospectus dated July 22, 2022 to which it relates, as amended or supplemented (the “Base Shelf Prospectus”), an |
|
| July 25, 2022 |
As filed with the Securities and Exchange Commission on July 25, 2022 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 25, 2022 Registration No. |
|
| July 11, 2022 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on July 11, 2022 Registration No. |
|
| July 11, 2022 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form F-10 (Form Type) IMV Inc. (Exact Name of Registrant as Specified in its Charter) Table 1-Newly Registered Securities Security Type Security Class Title Fee Calculation Rule or Instruction Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Unallocated (Unive |
|
| July 11, 2022 |
UNITED STATES Securities and Exchange Commission Washington, D.C. 20549 FORM F-X APPOINTMENT OF AGENT FOR SERVICE OF PROCESS AND UNDERTAKING A. Name of issuer or person filing (“Filer”): IMV Inc. B. (1) This is x an original filing for the Filer. ¨ an amended filing for the Filer. (2) Check the following box if you are filing the Form F-X in paper in accordance with Regulation S-T Rule 101(b)(9). |
|
| July 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registran |
|
| July 8, 2022 |
IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency Exhibit 99.1 Media Release IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. ? July 8, 2022 - IMV Inc. (?IMV? or the ?Company?) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX? platform to treat solid and hematologic cancers, today announced that on July 7, |
|
| June 30, 2022 |
IMV Announces Annual and Special Meeting of Shareholders Voting Results Exhibit 99.1 Media Release IMV Announces Annual and Special Meeting of Shareholders Voting Results DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. – June 30, 2022 - IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced the voting res |
|
| June 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registran |
|
| June 22, 2022 |
6-K 1 imv6knr.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JUNE, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dart |
|
| June 22, 2022 |
Exhibit 99.1 Media Release IMV Strengthens Its Financial Position With the $US10 Million Drawdown From Its Existing Long-Term Debt Facility IMV achieves predetermined milestone to access the remaining $US10 Million under its Debt Facility with Horizon Phase 2b AVALON trial in platinum-resistant ovarian cancer open for enrollment DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. ? June 22, 2022 - IMV Inc. |
|
| June 3, 2022 |
EX-99.3 4 exhibit99-3.htm FORM OF PROXY Exhibit 99.3 |
|
| June 3, 2022 |
NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS EX-99.1 2 exhibit99-1.htm NOTICE OF ANNUAL AND SPECIAL MEETING Exhibit 99.1 NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS NOTICE IS HEREBY GIVEN that the annual and special meeting of the shareholders (the “Meeting”) of IMV Inc. (the “Corporation”) will be held in virtual form only at 11:00 am ET (12:00 pm AT), on June 29, 2022, for the purposes of: 1. receiving the financial statements of |
|
| June 3, 2022 |
Exhibit 99.3 |
|
| June 3, 2022 |
Exhibit 99.2 IMV INC. NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS AND MANAGEMENT INFORMATION CIRCULAR OF IMV INC. May 31, 2022 130 Eileen Stubbs Avenue Tel (902) 492-1819 Suite 19 Fax (902) 492-0888 Dartmouth, Nova Scotia Web: http://www.imv-inc.com/ B3B 2C4 These materials are important and require your immediate attention. If you have questions or require assistance with voting your sha |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registran |
|
| May 25, 2022 |
Exhibit 99.1 May 25, 2022 1500 Robert-Bourassa Blvd., 7th Floor Montreal QC, H3A 3S8 www.computershare.com To: All Canadian Securities Regulatory Authorities NASDAQ Exchange Subject: IMV INC. Amended II Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General and Special Meeting Record Date for Notice |
|
| May 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registra |
|
| May 17, 2022 |
IMV Inc. to Present at the H.C. Wainwright Global Investment Conference Exhibit 99.1 Media Release IMV Inc. to Present at the H.C. Wainwright Global Investment Conference DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. - May 17, 2022 - IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX? platform to treat solid and hematologic cancers, today announced that members of IMV?s executive manageme |
|
| May 17, 2022 |
6-K 1 imv6knr.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF MAY, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmo |
|
| May 13, 2022 |
Unaudited Interim Condensed Consolidated Financial Statements March 31, 2022 Exhibit 99.1 Unaudited Interim Condensed Consolidated Financial Statements March 31, 2022 May 12, 2022 Management’s Responsibility for Financial Reporting The accompanying unaudited interim condensed consolidated financial statements of IMV Inc. (the “Corporation”) are the responsibility of management and have been approved by the Board of Directors. The unaudited interim condensed consolidated fi |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registrant |
|
| May 13, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Andrew Hall, Chief Executive Officer of IMV Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of IMV Inc. (the ?issuer?) for the interim period ended March 31, 2022. 2. No misrepresentations: Based on my knowledge, having exercised re |
|
| May 13, 2022 |
EX-99.2 3 exhibit99-2.htm MANAGEMENT DISCUSSION AND ANALYSIS FOR THE PERIOD ENDED MARCH 31, 2022 Exhibit 99.2 Management’s Report on Financial Position and Operating Results For the three months ended March 31, 2022 MANAGEMENT DISCUSSION AND ANALYSIS (“MD&A”) The following analysis provides a review of the unaudited interim condensed consolidated results of operations, financial condition, and cas |
|
| May 13, 2022 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.4 5 exhibit99-4.htm CFO CERTIFICATION Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Brittany Davison, Snr. VP Finance acting as Chief Financial Officer of IMV Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of IMV Inc. (the “issuer”) for the interim period ended March 31, |
|
| May 13, 2022 |
IMV Inc. Announces First Quarter 2022 Financial and Operational Results Exhibit 99.1 Media Release IMV Inc. Announces First Quarter 2022 Financial and Operational Results Positive clinical results in bladder cancer were presented at the AACR annual meeting, including 2 confirmed complete responses (CRs) and 3 partial responses (PRs) per RECIST v1.1; CRs and PRs were observed in patients previously treated with checkpoint inhibitors; Treatment with MVP-S/CPA and pembro |
|
| May 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registrant |
|
| May 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registrant |
|
| May 6, 2022 |
EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED MAY 6, 2022 Exhibit 99.1 Media Release IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022 DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. - May 6, 2022 - IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its nove |
|
| May 4, 2022 |
Exhibit 99.1 May 3, 2022 1500 Robert-Bourassa Blvd., 7th Floor Montreal QC, H3A 3S8 www.computershare.com To: All Canadian Securities Regulatory Authorities NASDAQ Exchange Subject: IMV INC. Amended Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General and Special Meeting Record Date for Notice of M |
|
| May 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registra |
|
| April 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registra |
|
| April 28, 2022 |
IMV’s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting Exhibit 99.1 Media Release IMV?s Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., April 28, 2022 - IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX? platform to treat solid and hematologic cancers, today announced the Company?s lead comp |
|
| April 22, 2022 |
6-K 1 imv6knr.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF APRIL, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Da |
|
| April 22, 2022 |
IMV Inc. Names Michael P. Bailey Chairman of The Board EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED APRIL 22, 2022 Exhibit 99.1 Media Release NOT FOR IMMEDIATE RELEASE IMV Inc. Names Michael P. Bailey Chairman of The Board Dartmouth, Nova Scotia and Cambridge, Mass. – April 22, 2022 - IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform |
|
| April 14, 2022 |
6-K 1 imv6knomrd.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF APRIL, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 |
|
| April 14, 2022 |
Exhibit 99.1 April 14, 2022 1500 Robert-Bourassa Blvd., 7th Floor Montreal QC, H3A 3S8 www.computershare.com To: All Canadian Securities Regulatory Authorities NASDAQ Exchange Subject: IMV INC. Dear Sir/Madam: We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer: Meeting Type : Annual General and Special Meeting Record Date for Notice of Meetin |
|
| April 11, 2022 |
EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED APRIL 8, 2022 Exhibit 99.1 Media Release IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting Combination of MVP-S/CPA and pembrolizumab showed encouraging clinical activity in advanced, metastatic bladder cancer patients, particularly in patients who had received prior immune checkpo |
|
| April 11, 2022 |
6-K 1 imv6knr.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF APRIL, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Da |
|
| April 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registra |
|
| April 6, 2022 |
IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting Exhibit 99.1 IMV to Present at IMMUNOLOGY? 2022, the AAI Annual Meeting DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass., April 6, 2022, -(BUSINESS WIRE)- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX? platform to treat solid and hematologic cancers, today announced the Company will present a poster at IMMUNOLOGY? 20 |
|
| April 4, 2022 |
IMV Inc. to Present at Two Upcoming Investor Conferences EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED APRIL 4, 2022 Exhibit 99.1 Media Release IMV Inc. to Present at Two Upcoming Investor Conferences DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass. - April 4, 2022 - IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematologic cancers, today announ |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registra |
|
| March 25, 2022 |
EX-FILING FEES 5 tm2210358d1ex107.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) IMV Inc. (Exact name of registrant as specified in its charter) Table 1 - Newly Registered Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title(1) Fee Calculation Rule Amount to be Registered(2) Proposed Maximum Offering Price Per Share Proposed Maximum Ag |
|
| March 25, 2022 |
As filed with the Securities and Exchange Commission on March 25, 2022 S-8 1 tm2210358d1s8.htm FORM S-8 As filed with the Securities and Exchange Commission on March 25, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 IMV Inc. (Exact name of registrant as specified in its charter) Canada Not applicable (State or other jurisdiction of incorporation or or |
|
| March 25, 2022 |
EX-4.1 2 tm2210358d1ex4-1.htm EXHIBIT 4.1 Exhibit 4.1 IMV INC. AMENDED STOCK OPTION PLAN 1. The Plan An amended stock option plan (the “Plan”), pursuant to which options to purchase common shares (the “Shares”) in the capital of IMV Inc. (the “Corporation”) may be granted to the directors, officers, employees and consultants of the Corporation and its subsidiaries, is hereby established on the ter |
|
| March 17, 2022 |
Exhibit 99.6 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, as the Chief Executive Officer of IMV Inc. certifies that, to the best of his knowledge and belief, the annual report on Form 40-F for the fiscal year ended December 31, 2021, which accompanies this certification, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of th |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registra |
|
| March 17, 2022 |
Exhibit 99.1 ANNUAL INFORMATION FORM FOR THE YEAR ENDED DECEMBER 31, 2021 March 16, 2022 Contents I. INTRODUCTION AND FORWARD-LOOKING STATEMENTS 1 II. CORPORATE STRUCTURE 2 III. GENERAL DEVELOPMENT OF THE BUSINESS 3 Overview 3 History 4 Recent Developments 4 Overview of the Last 3 Years 4 Year ended December 31, 2021 4 Year ended December 31, 2020 6 Year ended December 31, 2019 10 IV. DESCRIPTION |
|
| March 17, 2022 |
Exhibit 99.5 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Pierre Labb?, certify that: 1. I have reviewed this annual report on Form 40-F of IMV Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statem |
|
| March 17, 2022 |
Consent of Independent Registered Public Accounting Firm – PricewaterhouseCoopers LLP Exhibit 99.8 CONSENT OF REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in this Annual Report on Form 40-F of our report dated March 16, 2022, with respect to the consolidated financial statements of IMV Inc., which appears in Exhibit 99.2 to this Annual Report on Form 40-F of IMV Inc. We also consent to the incorporation by reference in the Registration Statements o |
|
| March 17, 2022 |
Exhibit 99.3 Management?s Report on Financial Position and Operating Results For the year ended December 31, 2021 MANAGEMENT DISCUSSION AND ANALYSIS (?MD&A?) The following analysis provides a review of the audited annual consolidated results of operations, financial condition, and cash flows for the year ended December 31, 2021 (?Fiscal 2021?), with information compared to the year ended December |
|
| March 17, 2022 |
Exhibit 99.2 Consolidated Financial Statements December 31, 2021 March 16, 2022 Management’s Responsibility for Financial Reporting The accompanying consolidated financial statements of IMV Inc. (the “Corporation”) are the responsibility of management and have been approved by the Board of Directors. The consolidated financial statements have been prepared by management in accordance with Intern |
|
| March 17, 2022 |
IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results Exhibit 99.1 Media Release NOT FOR IMMEDIATE RELEASE IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results First patient dosed in VITALIZE Phase 2B trial in relapsed/refractory DLBCL Metastatic bladder cancer cohort data from Phase 2 basket trial to be presented at late-breaking symposium at AACR Phase 2B Avalon trial in advanced ovarian cancer to start in second h |
|
| March 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 40-F (Check One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13(a) OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2021 Commission File Number: 001-38480 IMV Inc. (Exact name of Registrant as specified |
|
| March 17, 2022 |
EX-99.4 5 imv40fex99-4.htm SECTION 302 CEO CERTIFICATE Exhibit 99.4 CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 I, Andrew Hall, certify that: 1. I have reviewed this annual report on Form 40-F of IMV Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, |
|
| March 17, 2022 |
Exhibit 99.7 CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 The undersigned, as the Chief Financial Officer of IMV Inc. certifies that, to the best of his knowledge and belief, the annual report on Form 40-F for the fiscal year ended December 31, 2021, which accompanies this certification, fully complies with the requirements of Section 13(a) or 15(d), as applicable, of th |
|
| March 10, 2022 |
Exhibit 99.1 Media Release IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022 Dartmouth, Nova Scotia, and Cambridge, Mass., March 10, 2022 , IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, to |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registra |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registra |
|
| March 9, 2022 |
IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022 Exhibit 99.1 Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022 IMV’s DPX technology elicits a coordinated anti-tumor immune response involving natural killer cells in both translational and preclinical studies Clinical data from the Company’s basket study in advanced, metastatic bladder cancer will be |
|
| February 17, 2022 |
6-K 1 imv6knr.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF FEBRUARY, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite |
|
| February 17, 2022 |
Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV to Host a Webcast to Highlight its Immune-Educating DPX? Platform Event will feature Michael Kalos, Ph.D., member of IMV?s Board of Directors and internationally recognized expert in T cell therapy and immunotherapy Live webinar on Thursday, February 24th @ 8amET, registration details below Dartmouth, Nova Scotia and Cambridge, Mass. ? February |
|
| January 12, 2022 |
6-K 1 imv6knr.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 1 |
|
| January 12, 2022 |
EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED JANUARY 12, 2022 Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Combination with KEYTRUDA® (pembrolizumab) in Patients with r/r DLBCL First patient with relapsed/refractory DLBCL received treatment with maveropepimut-S (MVP-S) in combinati |
|
| January 5, 2022 |
6-K 1 imv6knr.htm REPORT OF FOREIGN PRIVATE ISSUER FOR THE MONTH OF JANUARY, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January, 2022 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 1 |
|
| January 5, 2022 |
IMV Inc. to Present at Two Upcoming Investor Events Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV Inc. to Present at Two Upcoming Investor Events Dartmouth, Nova Scotia and Cambridge, Mass. ? January 5, 2022 ? IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers today announced that members of IMV?s executive ma |
|
| December 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| December 27, 2021 |
FORM 51-102F3 MATERIAL CHANGE REPORT OF IMV INC. EX-99.1 2 tm2136276d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT OF IMV INC. 1. Name and Address of Company IMV Inc. (“IMV” or the “Corporation”) 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, Nova Scotia B3B 2C4 2. Date of Material Change December 17, 2021 3. News Release On December 20, 2021, IMV issued a news release through the services of Business Wire with respe |
|
| December 27, 2021 |
Exhibit 99.2 ? VENTURE LOAN AND SECURITY AGREEMENT ? ? Dated as of December?17, 2021 ? by and among ? HORIZON TECHNOLOGY FINANCE CORPORATION, a Delaware corporation (?Horizon?), [****************] [********************] ? as a Lender and Collateral Agent ? POWERSCOURT INVESTMENTS XXV, LP a Delaware limited partnership (?Powerscourt?, and together with Horizon, singularly and collectively, jointly |
|
| December 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| December 22, 2021 |
IMV Appoints Andrew Hall as Chief Executive Officer EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED DECEMBER 22, 2021 Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV Appoints Andrew Hall as Chief Executive Officer Dartmouth, Nova Scotia, and Cambridge, Mass., December 22, 2021 - IMV Inc. (NASDAQ: IMV; TSX: IMV), (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform |
|
| December 21, 2021 |
EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED DECEMBER 21, 2021 Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Data from the Bladder and MSI-High Cohorts Clinical benefit (complete responses, partial responses, and stable disease) observed in metastatic bladder cancer patients, inclu |
|
| December 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| December 20, 2021 |
Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility This facility supports the advancement of IMV?s lead candidate, maveropepimut-S (MVP-S) across a range of cancer indications, and the development of new DPX-based immunotherapies against cancer Dartmouth, Nova Scotia, and Cambridge, Mass., December |
|
| December 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| December 2, 2021 |
Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE Role of B Cells Induced by IMV?s Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress Translational data show that treatment with maveropepimut-S (MVP-S, previously known as DPX-Survivac) induces a sustained and effective anti-tumor immune response that involves both T and B cells Dartmouth, Nova Scotia, and Cambridg |
|
| December 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| November 30, 2021 |
Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer For the first time, maveropepimut-S is being evaluated in a neoadjuvant combination and in patients with breast cancer Primary results of the study are expected in 2023 Dartmouth, Nova Scotia, and Cambridge, Mass., November 30, 20 |
|
| November 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| November 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| November 23, 2021 |
IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED NOVEMBER 23, 2021 Exhibit 99.1 Media Release IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference Dartmouth, Nova Scotia and Cambridge, Mass., November 23, 2021 – IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platfor |
|
| November 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| November 22, 2021 |
IMV Inc. Announces Chief Financial Officer to Retire EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED NOVEMBER 22, 2021 Exhibit 99.1 Media Release IMV Inc. Announces Chief Financial Officer to Retire Dartmouth, Nova Scotia, and Cambridge, Mass., November 22, 2021. IMV Inc. (NASDAQ: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapies based on its novel DPX platform, today announced |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| November 12, 2021 |
IMV Inc. Announces Third Quarter 2021 Financial and Operational Update Exhibit 99.1 Exhibit 99.1 IMV Inc. Announces Third Quarter 2021 Financial and Operational Update Dartmouth, Nova Scotia, and Cambridge, Mass., November 10, 2021. IMV Inc. (“IMV” or “the Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing immune-educating cancer therapies, based on its novel DPX platform, that target solid and blood cancers while preserving patients’ quality of l |
|
| November 10, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Andrew Hall, Interim Chief Executive Officer of IMV Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the ?interim filings?) of IMV Inc. (the ?issuer?) for the interim period ended September 30, 2021. 2. No misrepresentations: Based on my knowledge, having |
|
| November 10, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.4 5 exhibit99-4.htm CFO CERTIFICATION Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Pierre Labbé, Chief Financial Officer of IMV Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of IMV Inc. (the “issuer”) for the interim period ended September 30, 2021. 2. No misrepresenta |
|
| November 10, 2021 |
EX-99.2 3 exhibit99-2.htm MANAGEMENT DISCUSSION AND ANALYSIS FOR THE PERIOD ENDED SEPTEMBER 30, 2021 Exhibit 99.2 Management’s Report on Financial Position and Operating Results For the three and nine months ended September 30, 2021 MANAGEMENT DISCUSSION AND ANALYSIS (“MD&A”) The following analysis provides a review of the unaudited interim condensed consolidated results of operations, financial c |
|
| November 10, 2021 |
Unaudited Interim Condensed Consolidated Financial Statements September 30, 2021 Exhibit 99.1 Unaudited Interim Condensed Consolidated Financial Statements September 30, 2021 November 10, 2021 Management?s Responsibility for Financial Reporting The accompanying unaudited interim condensed consolidated financial statements of IMV Inc. (the ?Corporation?) are the responsibility of management and have been approved by the Board of Directors. The unaudited interim condensed consol |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| November 9, 2021 |
EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED NOVEMBER 9, 2021 Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting • MVP-S treatment increased survivin-specific T and B cell tumor infiltration, further validating the MVP-S mechanism of action • Immunogenic/infla |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| November 4, 2021 |
Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV Inc. to Announce Third Quarter 2021 Results and Host a Conference Call and Webcast on November 11, 2021 Dartmouth, Nova Scotia, and Cambridge, Mass., November 4, 2021 , IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating cancer therapies, based on its novel DPX platform, to treat solid and blood |
|
| November 4, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regis |
|
| October 7, 2021 |
EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED OCTOBER 7, 2021 Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE Immunotherapeutic Benefits of the DPX Delivery Platform Featured in Two Poster Presentations at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics Poster presentations show that: • DPX generates peptide-specific, T cell-based immune responses that are more robust an |
|
| October 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regist |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regist |
|
| October 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regi |
|
| October 1, 2021 |
Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV?s DPX Delivery Technology to be Showcased in Two e-Posters at the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics Dartmouth, Nova Scotia, and Cambridge, Mass., September 30, 2021 ? IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-t |
|
| October 1, 2021 |
EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED OCTOBER 1, 2021 Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE Potential Response Predictors to IMV’s Lead Compound in the DeCidE Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presented at SITC Annual Meeting Dartmouth, Nova Scotia, and Cambridge, Mass., October 1st, 2021 - IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage |
|
| September 1, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the regi |
|
| September 1, 2021 |
IMV Inc. to Present at Three Investor Conferences in September EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED SEPTEMBER 1, 2021 Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV Inc. to Present at Three Investor Conferences in September Dartmouth, Nova Scotia and Cambridge, Mass. – September 1, 2021 – IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology company pioneering a novel class of immunotherapies against difficult-to-treat cancers, toda |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registr |
|
| August 11, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.3 4 exhibit99-3.htm CEO CERTIFICATION Exhibit 99.3 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Andrew Hall, Interim Chief Executive Officer of IMV Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of IMV Inc. (the “issuer”) for the interim period ended June 30, 2021. 2. No misrepresen |
|
| August 11, 2021 |
FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE EX-99.4 5 exhibit99-4.htm CFO CERTIFICATION Exhibit 99.4 FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Pierre Labbé, Chief Financial Officer of IMV Inc., certify the following: 1. Review: I have reviewed the interim financial report and interim MD&A (together, the “interim filings”) of IMV Inc. (the “issuer”) for the interim period ended June 30, 2021. 2. No misrepresentations |
|
| August 11, 2021 |
IMV Inc. Announces Second Quarter 2021 Financial and Operational Results EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED AUGUST 11, 2021 Exhibit 99.1 Media Release IMV Inc. Announces Second Quarter 2021 Financial and Operational Results Appointed Andrew Hall, Chief Business Officer, as interim CEO, Jeremy Graff, PhD as Chief Scientific Officer, Stanley Frankel, MD and Jose Iglesias, MD as Clinical Advisors Strengthened financial position and extended cash runway with the |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registr |
|
| August 11, 2021 |
Unaudited Interim Condensed Consolidated Financial Statements June 30, 2021 EX-99.1 2 exhibit99-1.htm INTERIM FINANCIAL STATEMENTS FOR THE PERIOD ENDED JUNE 30, 2021 Exhibit 99.1 Unaudited Interim Condensed Consolidated Financial Statements June 30, 2021 August 10, 2021 Management’s Responsibility for Financial Reporting The accompanying unaudited interim condensed consolidated financial statements of IMV Inc. (the “Corporation”) are the responsibility of management and h |
|
| August 11, 2021 |
Exhibit 99.2 Management?s Report on Financial Position and Operating Results For the three and six months ended June 30, 2021 MANAGEMENT DISCUSSION AND ANALYSIS (?MD&A?) The following analysis provides a review of the unaudited interim condensed consolidated results of operations, financial condition, and cash flows for the three and six months ended June 30, 2021 (?Q2 2021?), with information com |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registr |
|
| August 10, 2021 |
EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED AUGUST 10, 2021 Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer Final patient completed the study after more than 2 years of continuous treatment with maveropepimut-S (MVP-S) Median Overall Survival was 19.9 months, and overall survival rate was 44.9% |
|
| August 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registr |
|
| August 5, 2021 |
Exhibit 99.1 Media Release IMV Announces CEO Transition Frederic Ors to Step Down as CEO CBO Andrew Hall Appointed Interim CEO Board Initiating Search for Permanent Successor DARTMOUTH, Nova Scotia, August 4th, 2021, IMV Inc. (Nasdaq: IMV; TSX: IMV) (?IMV? or the ?Company?), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies, today announced that Fredric |
|
| August 3, 2021 |
6-K 1 210803imv6knr.htm REPORT OF FOREIGN ISSUER FOR THE MONTH OF AUGUST, 2021 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Da |
|
| August 3, 2021 |
EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED AUGUST 2, 2021 Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV Inc. to Announce Second Quarter 2021 Results and Host a Conference Call and Webcast on August 11, 2021 Dartmouth, Nova Scotia; August 2, 2021 – IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunothe |
|
| July 29, 2021 |
Filed by e3 Filing, Computershare 1-800-973-3274 - IMV Inc. - Form 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, N |
|
| July 29, 2021 |
IMV to Participate in the BTIG Virtual Biotechnology Conference Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV to Participate in the BTIG Virtual Biotechnology Conference Dartmouth, Nova Scotia; July 29, 2021 – IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies against difficult-to-treat cancers, today announced that members of IMV’s executive management te |
|
| July 21, 2021 |
FORM 51-102F3 MATERIAL CHANGE REPORT OF IMV INC. EX-99.1 2 tm2122904d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 FORM 51-102F3 MATERIAL CHANGE REPORT OF IMV INC. 1. Name and Address of Company IMV Inc. (“IMV” or the “Corporation”) 130 Eileen Stubbs Avenue, Suite 19, Dartmouth, Nova Scotia B3B 2C4 2. Date of Material Change July 14, 2021 3. News Release On July 15 and July 20, 2021, IMV issued news releases through the services of Business Wire with re |
|
| July 21, 2021 |
IMV Inc. Closes Previously Announced Public Offering EX-99.2 3 tm2122647d1ex99-2.htm EXHIBIT 99.2 Exhibit 99.2 IMV Inc. Closes Previously Announced Public Offering Dartmouth, Nova Scotia; July 20, 2021 – IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, announced today the closing of its previously-announced underwritten public offering (the “Offering”) of 14,285,714 units (the “Units”) at a |
|
| July 21, 2021 |
EX-99.1 2 tm2122647d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IMV INC. - and – COMPUTERSHARE TRUST COMPANY OF CANADA WARRANT INDENTURE July 20, 2021 TABLE OF CONTENTS Article 1 INTERPRETATION 6 1.1 Definitions 6 1.2 Words Importing the Singular 10 1.3 Interpretation not Affected by Headings 11 1.4 Day not a Business Day 11 1.5 Time of the Essence 11 1.6 Governing Law 11 1.7 Meaning of “outstanding” fo |
|
| July 21, 2021 |
IMV / IMV Inc. / FONDS DE SOLIDARITE DES TRAVAILLEURS DU QUEBEC - AMENDMENT NO. 1 Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* IMV INC. (Name of Issuer) Common Shares (Title of Class of Securities) 44974L103 (CUSIP Number) July 20, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| July 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada (Address of principal executive offices) Indi |
|
| July 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registran |
|
| July 16, 2021 |
EX-99.1 2 tm2122474d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 McCarthy Tétrault S.E.N.C.R.L., s.r.l. 500, Grande Allée Est, 9e étage Québec, QC G1R 2J7 Canada July 16, 2021 IMV Inc. 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, NS B3B 2C4 Dear Sirs/Mesdames: Re: IMV Inc. (the “Corporation”) We refer you to the registration statement on Form F-10 dated July 16, 2021 (the “Registration Statement”) of th |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registran |
|
| July 16, 2021 |
Filed Pursuant to General Instruction II.L. of Form F-10 File No. 333-249493 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement (the “Prospectus Supplement”), together with the accompanying short form base shelf prospectus dated June 26, 2020 to which it relates, as amended or supplemented, includin |
|
| July 15, 2021 |
Filed Pursuant to General Instruction II.L. of Form F-10 File No. 333-249493 No securities regulatory authority has expressed an opinion about these securities and it is an offence to claim otherwise. This prospectus supplement (the ?Prospectus Supplement?), together with the accompanying short form base shelf prospectus dated June 26, 2020 to which it relates, as amended or supplemented, includin |
|
| July 15, 2021 |
Exhibit 99.4 McCarthy T?trault S.E.N.C.R.L., s.r.l. 500, Grande All?e Est, 9e ?tage Qu?bec, QC G1R 2J7 Canada July 15, 2021 IMV Inc. 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, NS B3B 2C4 Dear Sirs/Mesdames: Re: IMV Inc. (the ?Corporation?) We refer you to the registration statement on Form F-10 dated July 15, 2021 (the ?Registration Statement?) of the Corporation to which this consent is exhibi |
|
| July 15, 2021 |
IMV Inc. Announces Pricing of Public Offering Exhibit 99.2 IMV Inc. Announces Pricing of Public Offering Dartmouth, Nova Scotia; July 15, 2021 ? IMV Inc. (?IMV? or the ?Corporation?) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, announced today the pricing of its previously-announced underwritten public offering (the ?Offering?) of 14,285,714 units (the ?Units?) at a price to the public of US$1.75 per Unit, for aggreg |
|
| July 15, 2021 |
EX-99.3 4 tm2120988d1ex99-3.htm EXHIBIT 99.3 Exhibit 99.3 IMV Inc. 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, NS B3B 2C4 Re: Registration Statement on Form F-10 We refer to the registration statement on Form F-10 dated July 15, 2021 (the “Registration Statement”) of IMV Inc. to which this consent is exhibited. We hereby consent to the use of our firm name on the face page of the Registration St |
|
| July 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registran |
|
| July 15, 2021 |
Exhibit 99.1 IMV Inc. 14,285,714 Common Shares and Warrants to Purchase 10,714,285 Common Shares UNDERWRITING AGREEMENT July 14, 2021 Wells Fargo Securities Canada, Ltd. Cantor Fitzgerald & Co. As Representatives of the several Underwriters c/o Wells Fargo Securities Canada, Ltd. 22 Adelaide Street West, Suite 2200 Toronto, Ontario, M5H 4E3 c/o Cantor Fitzgerald & Co. 499 Park Avenue New York, NY |
|
| July 14, 2021 |
Subject to completion, dated July 14, 2021 Filed Pursuant to General Instruction II.L. of Form F-10 File No. 333-249493 Information contained herein is subject to completion or amendment. A registration statement relating to these securities has been filed with the United States Securities Exchange Commission. This preliminary prospectus supplement and the accompanying base shelf prospectus shall not constitute an offer to sell or the soli |
|
| July 14, 2021 |
IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Units EX-99.1 2 tm2121075d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 IMV Inc. Files Preliminary Prospectus Supplement for Proposed Public Offering of Units Dartmouth, Nova Scotia; July 14, 2021 – IMV Inc. (“IMV” or the “Corporation”) (NASDAQ: IMV; TSX: IMV), a clinical-stage immuno-oncology corporation, has filed today a preliminary prospectus supplement (the “Supplement”) to its final short form base shelf |
|
| July 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registran |
|
| June 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registran |
|
| June 22, 2021 |
Annual and Special Meeting of Shareholders EX-99.1 2 exhibit99-1.htm REPORT OF VOTING RESULTS Exhibit 99.1 Annual and Special Meeting of Shareholders June 18, 2021 Report on Voting Results Pursuant to Section 11.3 of National Instrument 51-102 – Continuous Disclosure Obligations The annual and special meeting (the “Meeting”) of shareholders of IMV Inc. (the “Corporation”) was held on June 18, 2021. 82 shareholders holding 42,711,232 common |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registran |
|
| June 21, 2021 |
IMV Announces Annual and Special Meeting of Shareholders Voting Results EX-99.1 2 exhibit99-1.htm NEWS RELEASE DATED JUNE 18, 2021 Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV Announces Annual and Special Meeting of Shareholders Voting Results DARTMOUTH, Nova Scotia, June 18, 2021. IMV Inc. (“IMV” or the “Company”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company, today announced the voting results from its annual and special meeting of shar |
|
| June 9, 2021 |
Exhibit 99.1 Media Release FOR IMMEDIATE RELEASE IMV Announces Appointment of Jeremy R. Graff, Ph.D. as Chief Scientific Officer And Addition of Clinical Advisor Dr. Graff will lead IMV's research to continue the expansion of DPX- based immuno-oncology pipeline and the development of a comprehensive translational strategy to optimize clinical success Industry veteran Stanley Frankel, M.D. to advis |
|
| June 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2021 Commission File Number: 001-38480 IMV Inc. (Name of registrant) 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4, Canada Indicate by check mark whether the registran |
